Correspondence 0001193125-25-073631 from Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc.
Date: April 4, 2025 · CIK: 0001422142 · Accession: 0001193125-25-073631
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286284
Letter
Re: Whitehawk Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-286284 Acceleration Request
April 4, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill
Requested Date:
April 8, 2025
Requested Time:
4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Whitehawk Therapeutics , Inc. (the “ Company ”) hereby requests that its Registration Statement on Form S-3 (File No. 333-286284) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Robert Wernli at (619) 361-4805.
Sincerely,
WHITEHAWK THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 4, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill Re: Whitehawk Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-286284 Acceleration Request Requested Date: April 8, 2025 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Whitehawk Therapeutics , Inc. (the “ Company ”) hereby requests that its Registration Statement on Form S-3 (File No. 333-286284) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Robert Wernli at (619) 361-4805. Sincerely, WHITEHAWK THERAPEUTICS, INC. By: /s/ David J. Lennon, Ph.D. David J. Lennon, Ph.D. Chief Executive Officer cc: Stephen Rodin, Whitehawk Therapeutics, Inc. Dan Koeppen, Wilson Sonsini Goodrich & Rosati Robert Wernli, Wilson Sonsini Goodrich & Rosati